Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
HbA1c Improvement After HCV Clearance in HIV?
J Infect Dis; ePub 2017 Nov 18; Chaudhury, et al
No improvement in hemoglobin A1c (HbA1c) was observed following hepatitis C viral clearance irrespective of HIV, diabetes, or fibrosis stage, a recent study found. The study evaluated 251 participants with chronic hepatitis C virus (HCV) (31% HIV positive) pre- and post-DAA therapy (median follow-up 28 months). Researchers found:
- Changes in HbA1c and glucose were minimal and did not differ by sustained virologic response (SVR), HIV, diabetes, or fibrosis.
- Following SVR, mean change in HbA1c was -0.022 ±0.53%; however, total and low-density lipoprotein cholesterol increased significantly.
- Participants with HIV had smaller transaminase reductions after SVR.
Citation:
Chaudhury CS, Sheehan J, Chairez C, et al. No improvement in hemoglobin A1c following hepatitis C viral clearance in patients with and without HIV. [Published online ahead of print November 18, 2017]. J Infect Dis. doi:10.1093/infdis/jix517.